The inhibition of HIF1alfa (e.g., by hypoxia, danger signals) will change the phenotype of the macrophage from a pro-inflammatory M1 phenotype to a pro-reparatory (or alternatively activated) M2 phenotype (2).
Activation of their differentiation from the classic M1 macrophage phenotype is typically mediated by interleukin-4 (IL-4) and interleukin-13 (IL-13) (1). However, the molecular pathways that govern their differentiation have remained incompletely understood (1, 7, 11).
In M2 macrophages (CD68+ CD163+) the tricarboxylic acid (TCA) cycle is intact and participates in oxidative phosphorylation, providing ATP for energy (2, 3). This allows the generation of UDP-GlcNAc intermediates that are necessary for the glycosylation of M2-associated receptors, such as the mannose receptor (3).
The M2 type is characterized by expression of arginase-1, YM-1, Fizz-1, mannose receptors , scavenger receptors and chemokine genes, such as ccl1 gene , ccl17 gene , ccl22 gene , ccl16 gene , ccl18 gene and ccl24 gene (5). M2 macrophages are typically anti-inflammatory or inflammation-resolving
Yes, phenotypic markers: are CD68+, CD163+ (7, 8, 9, 10).
M2-like genes are arg1 gene, cd163 gene, MRC1, and vegfa gene (4).
M2 phenotype is triggered by CD4+ Th2 Cells & Cytokines such as interleukin-4 and interleukin-13 as well as anti-inflammatory cytokines , Interleukin-10 (IL-10) and Transforming growth factor beta (TGF-beta), or glucocorticoids (6, 7).
Yes, the transcription factors are Signal transducer and activator of transcription 3 (STAT3), Cyclic AMP-dependent transcription factor ATF-3 (ATF3), Glucocorticoid receptor (GR) (7, 8, 9, 10).
Interleukin-4, and Interleukin-13 are inducing stimuli of M2 macrophages (7, 8, 9, 10)
Secreted factors are Interleukin-10, Arginase, TGF beta (7, 8, 9, 10)
(1)
(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
(10)
(11)
see also:
Glycolysis & Macrophage polarization
Interleukin-4 (IL-4) & M2 macrophages (CD68+ CD163+)
THP-1 cell line
Tumor-Associated Macrophages (TAM)